Skip to main content

Table 2 Correlations between ULBP-3, ULBP-4 and ULBP-5 expression and well-established prognostic factors.

From: NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study

  Total ULBP3    ULBP4    ULBP5
    Low   High   Low   High   Low   High  
  N % N % N % N % N % N % N %
Age               
< 40
40-50
50-60
> = 60 		48
145
132
249 		8.4
25.3
23.0
43.4 		25
84
68
128 		8.2
27.5
22.3
42.0 		11
24
22
55 		9.8
21.4
19.6
49.1 		29
91
86
164 		7.8
24.6
23.2
44.3 		15
33
30
49 		11.8
26.0
23.6
38.6 		38
119
103
185 		8.5
26.7
23.1
41.6 		3
9
12
23 		6.4
19.1
25.5
48.9
Grade               
I
II
III 		80
282
203 		14.2
49.9
35.9 		45
160
96 		15.0
53.2
31.9 		10
43
57 		9.1
39.1
51.8 		51
181
134 		13.9
49.5
36.6 		13
67
43 		10.6
54.5
35.0 		62
219
157 		14.2
50.0
35.8 		2
21
23 		4.3
45.7
50.0
Histological type               
Ductal
Lobular 		513
53 		90.6
9.4 		281
20 		93.4
6.6 		102
8 		92.7
7.3 		330
37 		89.9
10.1 		113
10 		91.9
8.1 		396
43 		90.2
9.8 		43
3 		93.5
6.5
T-status               
T1
T2
T3/4 		211
272
72 		38.0
49.0
13.0 		113
142
39 		38.4
48.3
13.3 		40
54
17 		36.0
48.6
15.3 		118
180
60 		33.0
50.3
16.8 		57
61
6 		46.0
49.2
4.8 		159
209
64 		36.8
48.4
14.8 		19
26
2 		40.4
55.3
4.3
N-status               
N0
N1-3 		307
250 		55.1
44.9 		158
135 		53.9
46.1 		61
49 		55.5
44.5 		193
170 		53.2
46.8 		66
55 		54.5
45.5 		237
196 		54.7
45.3 		24
21 		53.3
46.7
ER-status               
Negative
Positive 		203
337 		37.6
62.4 		113
178 		38.8
61.2 		37
73 		33.6
66.4 		135
222 		37.8
62.2 		43
80 		35.0
65.0 		152
278 		35.3
64.7 		21
25 		45.7
54.3
PgR-status               
Negative
Positive 		223
313 		41.6
58.4 		130
159 		45.0
55.0 		42
68 		38.2
61.8 		141
215 		39.6
60.4 		51
72 		41.5
58.5 		158
267 		37.2
62.8 		26
21 		55.3
44.7
Her2-status               
Overexpression -
Overexpression + 		378
44 		80.9
19.1 		207
24 		89.6
10.4 		82
10 		89.1
10.9 		256
33 		88.6
11.4 		93
6 		93.9
6.1 		311
32 		90.7
9.3 		35
6 		85.4
14.6
Local Therapy               
MAST-RT
MAST+RT
BCS-RT
BCS+RT 		223
108
5
238 		38.9
18.8
0.9
41.5 		116
56
3
130 		38.0
18.4
1.0
42.6 		43
24
1
44 		38.4
21.4
0.9
39.3 		141
86
1
142 		38.1
23.2
0.3
38.4 		46
14
3
64 		36.2
11.0
2.4
50.4 		165
94
4
182 		37.1
21.1
0.9
40.9 		24
3
0
20 		51.1
6.4
0.0
42.6
Systemic therapy               
CT alone
HT alone
CT&HT
None 		112
75
18
369 		19.5
13.1
3.1
64.3 		65
32
10
198 		21.3
10.5
3.3
64.9 		23
10
2
77 		20.5
8.9
1.8
68.8 		81
52
13
224 		21.9
14.1
3.5
60.5 		20
16
1
90 		20.3
12.6
0.8
70.9 		93
60
11
281 		20.9
13.5
2.5
63.1 		8
5
1
33 		17.0
10.6
2.1
70.2
Total 574 100 305 100 112 100 370 100 127 100 445 100 47 100
  1. Missing values are not shown.
  2. AbbreviationsN number of patients; % percentage; ER estrogen receptor; PgR progesterone receptor; HER2 human epidermal growth factor receptor 2; MAST mastectomy; RT radiotherapy; BCS breast conservative surgery; ET endocrine therapy; CT chemotherapy.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us